PharmaVoice

AUGUST 3, 2022

How these latest executive personnel changes are impacting the industry.

264

264

PhRMA

AUGUST 3, 2022

As members of Congress continue to push forward misguided government price-setting policies under the guise of “negotiation,” patient advocates across the country have been speaking out in local media outlets about the potential consequences.

246

246

Pharmacy Times

AUGUST 3, 2022

Effective pharmacy managers help everyone to see the proverbial forest through the trees.

149

149

PharmaVoice

AUGUST 3, 2022

The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.

130

130

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmacy Times

AUGUST 3, 2022

Findings in a new trial show that dietary supplementation of resistant starch has the potential to decrease people’s risk of certain types of gastrointestinal cancers.

149

149

pharmaphorum

AUGUST 3, 2022

We all know that real-world data (RWD) from electronic health records (EHR) could boost clinical trial efficiency and improve patient outcomes – so what’s holding us back? It’s been more than two decades since the ground-breaking potential of using electronic health records (EHR) to inform clinical research was first mooted. Since then, progress has been slow, but the industry now has everything it needs to close the feedback loop between science, evidence, and care, said speakers at a recent Co

Cerner 124

Cerner FDA 124

PhRMA

AUGUST 3, 2022

Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines , American medical innovation and our health care system as a whole. But there is another consequence that we can’t leave out: the impact this proposal will have on the biopharmaceutical industry’s contributions to American jobs and the economy.

113

113

Pharmacy Times

AUGUST 3, 2022

As leaders, we should ask ourselves if any of our people might feel imposter syndrome and what can we do to calm their anxiety and boost their confidence.

132

132

European Pharmaceutical Review

AUGUST 3, 2022

Ph. Eur. The European Pharmacopoeia (Ph. Eur.) Commission has established the mRNAVAC Working Party to begin working on quality standards to support the emerging field of messenger RNA (mRNA) vaccines. The newly created Working Party’s first task will be to develop a consolidated strategy for future standards addressing these vaccines and their components.

Vaccines 105

Vaccines 105

Pharmacy Times

AUGUST 3, 2022

Pharmacist interventions can provide patient-specific guidance to identify and solve problems with medication regimens to ensure optimal outcomes.

130

130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

AUGUST 3, 2022

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases. The agreement with Poseida is by far the larger of the two, with Roche paying $110 million upfront to license rights to off-the-shelf CAR-T therapies aimed at haematological cancers, including one targeting BCMA on phase 1 testing and another targeting CD19 and CD20 that is due to start trials in 2023 – known as the tier 1 candidates.

98

98

Pharmacy Times

AUGUST 3, 2022

Participants who initiated treatment with Biktarvy demonstrated superior hepatitis B virus (HBV) DNA suppression and HBV e-antigen seroconversion.

123

123

Pharma Tutor

AUGUST 3, 2022

HERBAL / NATURAL INGREDIENTS FOR SKIN NOURISHMENT FROM A TO Z. About Authors. Avdesh Thassu. MPharm (Nat. Chem.); MBA(Mkt.). admin. Wed, 08/03/2022 - 15:44. Tags. Articles.

59

59

Pharmacy Times

AUGUST 3, 2022

Increasing population immunity decreased transmission of COVID-19 and allowed for reductions in quarantine and testing, encouraging 2-dose vaccine and booster uptake.

Immunization 123

Immunization Vaccines 123

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

AUGUST 3, 2022

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus BioSciences’ Cimerli – which its developer claims is the first to be fully interchangeable with the originator product. Cimerli isn’t the first biosimilar of Lucentis (ranibizumab) to be given the green light to be sold in the US, as that accolade goes to Samsung Bioepis’ Byooviz , which was cleared by the FDA last September.

FDA 59

FDA Labelling 59

Pharmacy Times

AUGUST 3, 2022

Ranibizumab-eqrn is the only biosimilar approved for all 5 Lucentis indications.

FDA 123

FDA 123

pharmaphorum

AUGUST 3, 2022

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in the class. The five-year-old Chinese company – which is developing drugs for age-related degenerative diseases – said it will use the proceeds of the Series B to support the clinical development of its RIPK1 inhibitors as well as to expand its pipeline of drug candidates in other classes.

Immunization 59

Immunization 59

Pharmacy Times

AUGUST 3, 2022

The next-generation vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain and an Omicron variant.

Vaccines 94

Vaccines 94

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

PharmExec

AUGUST 3, 2022

Value-based price for access (VBPA) may increase access of specialty drugs for patients.

59

59

Pharmacy Times

AUGUST 3, 2022

Gamma-delta T-cells undergo a biochemical change that leads them to spur the growth of tumors that previously restricted.

94

94

Pharmaceutical Technology

AUGUST 3, 2022

Rigel Pharmaceuticals has signed a licence agreement with Forma Therapeutics for developing, producing and marketing olutasidenib to potentially treat relapsed/refractory acute myeloid leukaemia (R/R AML) and other types of cancer. . Olutasidenib, an investigational agent, is an oral, small molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1) that attaches to and hinders mutated IDH1 enzymes.

FDA 59

FDA 59

Pharmacy Times

AUGUST 3, 2022

Dermala helps support hormonal balance, which may help in the treatment of acne.

65

65

The Social Pharmacist

AUGUST 3, 2022

Billions of searches and site visits roll daily in thousands of web pages. As a valuable and sustainable marketing channel in organic search, optimizing the best organic keyword drives profitable traffic to your pharmacy website. Google enables a better user experience by matching a person’s intent with the appropriate page on the web. Your page doesn’t stand a chance in the various competition in the industry unless you optimize it accordingly.

52

52

Pharmacy Times

AUGUST 3, 2022

Ezetimibe (Zetia) is an inhibitor of intestinal cholesterol and related phytosterol absorption indicated as an adjunct to diet to reduce elevated total cholesterol.

65

65

pharmaphorum

AUGUST 3, 2022

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cancer (SCLC). In the RESILIENT study, Onivyde – a liposomal formulation of the well-established cytotoxic drug irinotecan – was unable to improve overall survival when used as a monotherapy after first-line platinum chemotherapy for SCLC, when compared to generic therapy topotecan.

Chemotherapy 52

Chemotherapy FDA 52

Pharmacy Times

AUGUST 3, 2022

IMscin001 analysis shows non-inferior levels of the cancer immunotherapy in the blood compared with intravenous infusion in individuals with advanced non–small cell lung cancer.

65

65

Pharmaceutical Technology

AUGUST 3, 2022

Gilead Sciences has reported a 1% growth in revenue to $6.3bn in the second quarter (Q2) of 2022 as against $6.2bn in the year-ago quarter. The company attributed the revenue rise to enhanced sales in HIV and oncology products, which was offset partially by reduced sales of Veklury (remdesivir) and hepatitis C virus (HCV) medicines. For the three months ended on 30 June 2022, diluted earnings per share (EPS) declined to $0.91 from $1.21 in Q2 2021.

52

52

Pharmaceutical Commerce

AUGUST 3, 2022

Association’s director general recommends air cargo developments be closely monitored in second half of year.

52

52

Pharmaceutical Technology

AUGUST 3, 2022

The discovery of a new chemical entity (NCE) that could potentially lead the way to a ground-breaking therapeutic treatment is an exciting prospect for any chemist. The potential to use these scientific breakthroughs to make a real difference to patients’ lives is what drives many highly skilled scientists to the world of drug development. Yet commercialising a drug is no easy journey, hence why just 10% of new drug candidates succeed in making it to market.

Dosage 52

Dosage 52

Pharma Times

AUGUST 3, 2022

Deal represents part of Boehringer Ingelheim’s strategy to provide breakthrough cancer therapies

49

49

Pharmaceutical Technology

AUGUST 3, 2022

The proportion of pharmaceutical companies hiring for internet of things related positions rose in July 2022 compared with the equivalent month last year, with 18.2% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 14.6% of companies who were hiring for internet of things related jobs a year ago but a decrease compared to the figure of 19.7% in June 2022.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharma Times

AUGUST 3, 2022

The sites will maximise local and global benefits of NHS, research, industry and community partnerships

49

49

The Social Pharmacist

AUGUST 3, 2022

Organic Keywords for Pharmacy Website. Billions of searches and site visits roll daily in thousands of web pages. As a valuable and sustainable marketing channel in organic search, optimizing the best organic keyword drives profitable traffic to your pharmacy website. Google enables a better user experience by matching a person’s intent with the appropriate page on the web.

40

40